FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)

View source ↗

Summary

FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) submitted by Avvisto Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperprolactinemia
• Parkinson Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• CYCLOSET (BROMOCRIPTINE MESYLATE)

Snippet

SUPPL AP for CYCLOSET (BROMOCRIPTINE MESYLATE)